BLK Pharma Secures Hundreds of Millions in RMB in New Strategic Funding Round to Advance China's Bioprocessing Innovation

VCBeat has learned that BIO-LINK Pharmaceutical Technology (Shanghai) Co., Ltd. (“BIO-LINK”) has recently successfully completed a new round of strategic financing, with the total amount reaching hundreds of millions of RMB.This round of financing was led by Cathay Capital, with participation from multiple investment institutions including Alwin Investment, Haihe Asymchem Industrial Fund, SCGC, Haiwang Capital, and Wanwu Venture Capital; HAOYUE CAPITAL served as the exclusive financial advisor.This financing will provide significant capital support for BIO-LINK’s market expansion and product R&D, further accelerating the company’s domestic and international market deployment as well as its technological innovation and iteration.

Since its inception, BIO-LINK has been committed to overcoming critical bottlenecks in the field of bioprocessing, focusing on providing efficient, safe, and competitive process solutions for biologics such as vaccines, antibody drugs, recombinant proteins, and cell and gene therapies.The company focuses on key equipment and consumables for biopharmaceutical process units, including cell culture, single-use buffer preparation and storage, chromatography, clarification filtration, and hydration, while also providing process development and product validation services.

As an innovation-driven enterprise, BIO-LINK places great emphasis on R&D investment. Each product line is supported by dedicated R&D platforms and specialized teams, continuously launching self-developed products for key process steps, which has significantly enhanced the overall market competitiveness and technological sophistication of its product portfolio. To date, the company has secured nearly 200 technical patents and obtained domestic and international certifications, including ISO 9001, ISO 13485, CNAS, and CMA, ensuring high-quality standards and regulatory compliance for its products in the global market.

This year, BIO-LINK actively participated in major industry events both domestically and internationally. In collaboration with industry partners, it jointly established the “Specialized Branch for Antibody Drugs” and launched initiatives such as the “2024 Smart Bioprocessing Tour,” which focused on key bioprocessing technologies. By engaging directly with customers through face-to-face dialogues, BIO-LINK addressed the challenges they face in “cost reduction and efficiency enhancement.” Through partnerships with industry experts and the sharing of cutting-edge market insights and critical technical expertise, BIO-LINK provided valuable opportunities for industry exchange, earning widespread acclaim and positive feedback from its customer base.

Leveraging these innovative achievements and market-enabling initiatives, BIO-LINK has gradually emerged as a professional supplier in the biopharmaceutical industry, recognized for both its innovation and reliability, and has gained widespread recognition from numerous biopharmaceutical companies.

Mr. Chen Zhi, Chairman of BIO-LINK“The company expresses its gratitude to the investors for their attention and support. BIO-LINK will continue to focus on breakthroughs in core technologies, accelerate the enrichment and upgrading of its product portfolio, and promote the adoption of efficient, cost-effective biopharmaceutical solutions. Confident in its partnership with the investors, BIO-LINK is committed to empowering biotechnology and injecting strong momentum into the development of China’s biopharmaceutical industry.”

The successful completion of this financing round marks a further enhancement of BIO-LINK’s influence in the biopharmaceutical sector. Looking ahead, empowered by both capital and technology, we believe that BIO-LINK will leverage forward-looking innovation and high-quality products to overcome bioprocessing bottlenecks, thereby helping the industry access a broader future.